IS2877B - Lagskipt tafla, sem inniheldur pravastatín og aspirín, og aðferð - Google Patents

Lagskipt tafla, sem inniheldur pravastatín og aspirín, og aðferð

Info

Publication number
IS2877B
IS2877B IS7889A IS7889A IS2877B IS 2877 B IS2877 B IS 2877B IS 7889 A IS7889 A IS 7889A IS 7889 A IS7889 A IS 7889A IS 2877 B IS2877 B IS 2877B
Authority
IS
Iceland
Prior art keywords
aspirin
pravastatin
layer containing
tablet containing
containing pravastatin
Prior art date
Application number
IS7889A
Other languages
English (en)
Other versions
IS7889A (is
Inventor
Loutfy Benkerrour
Olivier Galley
Francoise Quinet
Peter Timmins
Admassu Abebe
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32505946&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IS2877(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of IS7889A publication Critical patent/IS7889A/is
Publication of IS2877B publication Critical patent/IS2877B/is

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
    • A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
IS7889A 2002-12-11 2005-06-10 Lagskipt tafla, sem inniheldur pravastatín og aspirín, og aðferð IS2877B (is)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/316,424 US20040115265A1 (en) 2002-12-11 2002-12-11 Multilayered tablet containing pravastatin and aspirin and method
PCT/US2003/038774 WO2004052289A2 (en) 2002-12-11 2003-12-03 Multilayered tablet containing pravastatin and aspirin

Publications (2)

Publication Number Publication Date
IS7889A IS7889A (is) 2005-06-10
IS2877B true IS2877B (is) 2014-04-15

Family

ID=32505946

Family Applications (1)

Application Number Title Priority Date Filing Date
IS7889A IS2877B (is) 2002-12-11 2005-06-10 Lagskipt tafla, sem inniheldur pravastatín og aspirín, og aðferð

Country Status (17)

Country Link
US (1) US20040115265A1 (is)
EP (1) EP1581194B1 (is)
JP (1) JP2006511520A (is)
AT (1) ATE401061T1 (is)
AU (1) AU2003297689A1 (is)
CY (1) CY1108414T1 (is)
DE (1) DE60322264D1 (is)
DK (1) DK1581194T3 (is)
ES (1) ES2308040T3 (is)
IS (1) IS2877B (is)
MY (1) MY140947A (is)
NO (1) NO338696B1 (is)
PL (1) PL206190B1 (is)
PT (1) PT1581194E (is)
SI (1) SI1581194T1 (is)
TW (1) TWI361700B (is)
WO (1) WO2004052289A2 (is)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4343948B2 (ja) 2003-04-29 2009-10-14 オレキシジェン・セラピューティクス・インコーポレーテッド 体重減少に影響を及ぼすための組成物
US8163797B2 (en) * 2003-12-31 2012-04-24 Actavis Elizabeth Llc Method of treating with stable pravastatin formulation
EP1830832A1 (en) * 2004-12-30 2007-09-12 Genzyme Corporation Zinc-containing treatments for hyperphosphatemia
US20060251722A1 (en) * 2005-05-03 2006-11-09 Novavax, Inc. Multi-component vitamin and mineral supplement for the optimal absorption of components
CA2620406A1 (en) * 2005-09-02 2007-03-08 Genzyme Corporation Method for removing phosphate and polymer used therefore
EP1945196A2 (en) * 2005-11-08 2008-07-23 Genzyme Corporation Magnesium-containing polymers for hyperphosphatemia
ES2761812T3 (es) 2005-11-22 2020-05-21 Nalpropion Pharmaceuticals Inc Composición y métodos de aumento de la sensibilidad a la insulina
WO2007072060A2 (en) * 2005-12-23 2007-06-28 Cipla Limited Particles comprising a core containing a hmg-coa reductase inhibitor and coated with a film
EP1970055B1 (en) 2005-12-29 2010-11-24 Osmotica Kereskedelmi És Szolgáltató Kft Multi-layered tablet with triple release combination
US8916195B2 (en) 2006-06-05 2014-12-23 Orexigen Therapeutics, Inc. Sustained release formulation of naltrexone
WO2008005217A2 (en) * 2006-07-05 2008-01-10 Genzyme Corporation Iron(ii)-containing treatments for hyperphosphatemia
US8765178B2 (en) * 2006-07-19 2014-07-01 Watson Laboratories, Inc. Controlled release formulations and associated methods
JP2010509367A (ja) * 2006-11-09 2010-03-25 オレキシジェン・セラピューティクス・インコーポレーテッド 積層製剤
MX2009004871A (es) 2006-11-09 2009-06-16 Orexigen Therapeutics Inc Paquete de dosificacion unitaria y metodos para administrar medicaciones de perdida de peso.
PL2134351T3 (pl) 2007-03-13 2017-10-31 Jds Therapeutics Llc Sposoby i kompozycje do przedłużonego uwalniania chromu
WO2009002867A2 (en) * 2007-06-26 2008-12-31 Nutrition 21, Inc. Multiple unit dosage form having a therapeutic agents in combination with a nutritional supplement
AU2008309287B2 (en) * 2007-10-12 2014-10-30 Ferring International Center Sa Process for the manufacure of a pharmaceutical product comprising citric acid, magnesium oxide, potassium bicarbonate and sodium picosulfate, pharmaceutical composition comprising granules obtained by such process and intermediate
WO2009158114A1 (en) 2008-05-30 2009-12-30 Orexigen Therapeutics, Inc. Methods for treating visceral fat conditions
CA2785822C (en) 2010-01-11 2019-06-25 Orexigen Therapeutics, Inc. Methods of providing weight loss therapy in patients with major depression
TR201005325A2 (tr) 2010-06-30 2012-01-23 Bi̇lgi̇ç Mahmut Atorvastatin ve aspirin içeren farmasötik formülasyonlar
KR20120068277A (ko) * 2010-12-17 2012-06-27 한미사이언스 주식회사 ＨＭＧ－ＣｏＡ 환원효소 억제제 및 아스피린을 포함하는 약제학적 복합제제
EP2668008A4 (en) * 2011-01-28 2018-01-24 Intouch Technologies, Inc. Interfacing with a mobile telepresence robot
KR20150016405A (ko) 2012-06-06 2015-02-11 오렉시젠 세러퓨틱스 인크. 과체중 및 비만의 치료 방법
EP2810644A1 (en) * 2013-06-06 2014-12-10 Ferrer Internacional, S.A. Oral formulation for the treatment of cardiovascular diseases
MX2018009748A (es) 2016-02-11 2019-02-07 Nutrition 21 Llc Composiciones que contienen cromo para mejorar la salud y el estado físico.
JP7109748B2 (ja) * 2018-12-11 2022-08-01 日本ジェネリック株式会社 アジルサルタンとアムロジピンベシル酸塩含有固形製剤及び固形製剤の製造方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4590183A (en) * 1985-04-22 1986-05-20 Sterling Drug Inc. Gastric cytoprotection with sodium thiosulfate in oral administration of aspirin
JP3172749B2 (ja) * 1992-02-17 2001-06-04 ライオン株式会社 イブプロフェン含有製剤
IT1255522B (it) * 1992-09-24 1995-11-09 Ubaldo Conte Compressa per impiego terapeutico atta a cedere una o piu' sostanze attive con differenti velocita'
IT1264517B1 (it) * 1993-05-31 1996-09-24 Ekita Investments Nv Compressa farmaceutica atta al rilascio in tempi successivi dei principi attivi in essa veicolati
FR2772615B1 (fr) * 1997-12-23 2002-06-14 Lipha Comprime multicouche pour la liberation instantanee puis prolongee de substances actives
US6235311B1 (en) * 1998-03-18 2001-05-22 Bristol-Myers Squibb Company Pharmaceutical composition containing a combination of a statin and aspirin and method
EP2332522A3 (en) * 1998-03-19 2011-12-07 Bristol-Myers Squibb Company Biphasic controlled release delivery system for high solubility pharmaceuticals and method
US6669955B2 (en) * 2001-08-28 2003-12-30 Longwood Pharmaceutical Research, Inc. Combination dosage form containing individual dosage units of a cholesterol-lowering agent, an inhibitor of the renin-angiotensin system, and aspirin

Also Published As

Publication number Publication date
PL377265A1 (pl) 2006-01-23
WO2004052289A3 (en) 2005-03-24
EP1581194A2 (en) 2005-10-05
US20040115265A1 (en) 2004-06-17
AU2003297689A1 (en) 2004-06-30
MY140947A (en) 2010-02-12
TW200505432A (en) 2005-02-16
NO338696B1 (no) 2016-10-03
NO20052734L (no) 2005-07-07
CY1108414T1 (el) 2014-02-12
TWI361700B (en) 2012-04-11
SI1581194T1 (sl) 2008-12-31
ATE401061T1 (de) 2008-08-15
IS7889A (is) 2005-06-10
PT1581194E (pt) 2008-09-24
DE60322264D1 (de) 2008-08-28
PL206190B1 (pl) 2010-07-30
DK1581194T3 (da) 2008-10-20
NO20052734D0 (no) 2005-06-07
EP1581194A4 (en) 2006-03-15
JP2006511520A (ja) 2006-04-06
AU2003297689A8 (en) 2004-06-30
EP1581194B1 (en) 2008-07-16
ES2308040T3 (es) 2008-12-01
WO2004052289A2 (en) 2004-06-24

Similar Documents

Publication Publication Date Title
IS2877B (is) Lagskipt tafla, sem inniheldur pravastatín og aspirín, og aðferð
GB0228196D0 (en) Split barrier layer including nitrogen-containing portion and oxygen-containing portion
AU2003251642A1 (en) Laser markable carrier unit
PE20000349A1 (es) Composicion farmaceutica que contiene una combinacion de una estatina y aspirina
MXPA02012638A (es) Peliculas de barrera de alta humedad.
ATE279915T1 (de) Mehrschichttablette zur verabreichung einer fixen kombination von tramadol und diclofenac
AR017749A1 (es) Estructura de multiples estratos
DE50007387D1 (de) Strahlungshärtbare verbundschichtplatte oder -folie
ATE480735T1 (de) Behälter zur lagerung von flüssiggas
PE20120542A1 (es) Formas de dosificacion solidas de valsartan, amlodipina e hidroclorotiazida y metodo para elaborarlas
NO20073277L (no) Flerlags laminert film for pakninger
MX2007010224A (es) Uso de un catalizador de varias capas para producir anhidrido ftalico.
ATE374425T1 (de) Zweilagige schutzschicht
DE50006328D1 (de) Transparente biaxial orientierte polyolefinfolie
AU2003240976A1 (en) Medical multilayer film structure
AU2003285237A8 (en) Barrier layer for thick film dielectric electroluminescent displays
MX2007008092A (es) Tubo de proteccion termica.
TH69755A (th) ยาเม็ดชนิดหลายชั้นซึ่งมีพราวาสเตติน และแอสไพริน และวิธี
AU2003244318A1 (en) Transparent laminated film having barrier property and method for production thereof
AR025301A1 (es) Estructuras de barrera de capas multiples y proceso para preparar las mismas.
GT199800174A (es) Estructura absorbente en capas.
AU2003266636A1 (en) Laminate comprising silver layer and, formed thereon, layer for stabilizing the same
AU2002325212A1 (en) Immobilized asymmetric double lipid layers
AU2002362467A1 (en) Multi-layer articles including a fluoroelastomer layer and a barrier layer and method of making the same
GT199800172A (es) Estructura absorbente en capas con una region de capa heterogenea.